Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2008 on request of the Sponsor.
On 11 September 2002, orphan designation (EU/3/02/112) was granted by the European Commission to Interface International Consultancy Limited, United Kingdom, for doxorubicin carbon/iron magnetically targeted microparticles for the treatment of hepatocellular carcinoma.
Treatment of hepatocellular carcinoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: